Peter Edman

Member of the Board of Directors

Finansinspektionen (Sweden) Files from Sweden

Compiled from cited public records — every figure names the disclosure it came from, none copied from any wealth ranking. How we calculate this.

Issuers on file
2
issuers named in insider transaction reports filed to Finansinspektionen (FI) in Sweden

Not measurable for this profile: Reconstructed positions · 1-day change

Trading activity Apr 6, 2018 – Mar 14, 2024

Peter Edman reported 11 transactions between Apr 6, 2018 and Mar 14, 2024. The buy and sell totals below count only codes SACQ, SDIS.

Open-market buys (SACQ)
612.2K SEK
7 purchases on file priced rows only
Open-market sales (SDIS)
175.0K SEK
1 sale on file priced rows only
All reported transactions
11
every code, including awards and exercises
Pattern
No transaction in the final 12 months of the window
last 12 months of the window

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

3 insiders bought Xbrane Biopharma AB shares worth 476,553 SEK between Dec 18, 2020 and Jan 15, 2021

Cluster buying

3 different insiders made 4 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

3 insiders bought Xbrane Biopharma AB shares worth 476,553 SEK between Dec 18, 2020 and Jan 15, 2021
Date Insider Transaction Shares Price Value Filing
Dec 18, 2020 Peter Edman SACQ Acquisition 2,253 72.76 SEK 163,928 SEK FI filing ↗
Jan 5, 2021 Karl Martin Erik Åmark SACQ Acquisition 805 77.00 SEK 61,985 SEK FI filing ↗
Jan 8, 2021 Karl Martin Erik Åmark SACQ Acquisition 1,150 81.60 SEK 93,840 SEK FI filing ↗
Jan 15, 2021 Christina Ivers SACQ Acquisition 2,000 78.40 SEK 156,800 SEK FI filing ↗

Total of the rows above: 476,553 SEK, in the currency the filings report.

Source: Finansinspektionen (Sweden); every row links to where it was published. Event computed Sep 14, 2026.

3 insiders bought Xintela AB shares worth 172,200 SEK between May 24, 2019 and Jun 3, 2019

Cluster buying

3 different insiders made 4 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

3 insiders bought Xintela AB shares worth 172,200 SEK between May 24, 2019 and Jun 3, 2019
Date Insider Transaction Shares Price Value Filing
May 24, 2019 Gunnar Telhammar SACQ Acquisition 5,000 5.46 SEK 27,300 SEK FI filing ↗
May 31, 2019 Gunnar Telhammar SACQ Acquisition 5,000 4.98 SEK 24,900 SEK FI filing ↗
May 31, 2019 Peter Edman SACQ Acquisition 15,000 4.80 SEK 72,000 SEK FI filing ↗
Jun 3, 2019 Evy Lundgren Åkerlund SACQ Acquisition 10,000 4.80 SEK 48,000 SEK FI filing ↗

Total of the rows above: 172,200 SEK, in the currency the filings report.

Source: Finansinspektionen (Sweden); every row links to where it was published. Event computed Sep 14, 2026.

Reported transactions

Price 0.00 is a real reported figure on allotments, gifts and option exercises — not a missing number. The 11 most recent rows are grouped into 10 lines by date, company and transaction type — open a line to see every lot with its own source link.

How to read this list

Every row is one insider transaction as reported to FI, with a link back to the FI register filtered to that issuer and publication date. FI publishes no per-report permalink, so the link is a search, not a document. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. Xbrane Biopharma AB SSUB Subscriptionnot a buy/sell decision 15,000 shares 172.5K SEK at 11.50 SEK FI filing ↗
  2. Xbrane Biopharma AB SACQ Acquisition 2,253 shares 163.9K SEK at 72.76 SEK FI filing ↗
  3. Xbrane Biopharma AB SDIS Disposal 2,529 shares 175.0K SEK at 69.20 SEK FI filing ↗
  4. Xbrane Biopharma AB SACQ Acquisition 2,529 shares 175.0K SEK at 69.20 SEK FI filing ↗
  5. Xbrane Biopharma AB SACQ Acquisition 2,247 shares 75.3K SEK at 33.50 SEK FI filing ↗
  6. Xintela AB SACQ Acquisition 15,000 shares 72.0K SEK at 4.80 SEK FI filing ↗
  7. Xbrane Biopharma AB SACQ Acquisition 540 shares 21.2K SEK at 39.30 SEK FI filing ↗
  8. Xbrane Biopharma AB SSUB Subscriptionnot a buy/sell decision 117 shares 3.5K SEK at 30.00 SEK FI filing ↗
  9. Xbrane Biopharma AB SSUB Subscriptionnot a buy/sell decision 2,343 shares 70.3K SEK at 30.00 SEK FI filing ↗
  10. Xbrane Biopharma AB SACQ Acquisition × 2 3,750 shares 104.8K SEK
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    1,500 61.04 SEK 91.6K SEK FI filing ↗
    2,250 5.88 SEK 13.2K SEK FI filing ↗

Reconstructed positions

We hold no share-level ownership disclosure naming Peter Edman. Anything this person is known to own appears in the stated-assets section above, quoted and attributed — we do not estimate what is missing.

Sources

Every figure on this page is quoted from the public record named beside it, with the date it was true. Nothing here is our own calculation.

Think a number here is wrong? Check the named disclosure and its date against the tables above — how to report it.

Profile record last refreshed Sep 14, 2026.